Multiple sclerosis (MS) is considered a primary autoimmune disease; however, this view is increasingly being challenged in basic and clinical science arenas because of the growing body of clinical trials' data showing that exclusion of immune cells from the CNS only modestly slows disease progression to disability. Accordingly, there is significant need for expanding the scope of potential disease mechanisms to understand the etiology of MS. Concomitantly, the use of a broader range of pre-clinical animal models for characterizing existing efficacious clinical treatments may elucidate additional or unexpected mechanisms of action for these drugs that augment insight into MS etiology. Herein, we explore the in vivo mechanism of action of dimethyl fumarate, which has been shown to suppress oxidative stress and immune cell responses in psoriasis and MS. Rather than studying this compound in the context of an experimental autoimmuneinduced attack on the CNS, we have used a genetic model of hypomyelination, male rumpshaker (rsh) mice, which exhibit oligodendrocyte metabolic stress and startle-induced subcortical myoclonus during development and into adulthood. We find that myoclonus is reduced 30-50% in treated mutants but we do not detect substantial changes in metabolic or oxidative stress response pathways, cytokine modulation, or myelin thickness (assessed by ANOVA). All procedures involving vertebrate animals in this study were reviewed and approved by the IACUC committee at Wayne State University. Keywords: leukodystrophy, neurodegeneration, neuroprotection, oxidative stress, Tecfidera. Increasingly, the investigation of neurodegenerative diseases is shifting from the clinical setting, wherein most studies focus on case reports, patient outcomes, and the description and cataloging of pathology, to the basic and translational science realms which seek molecular understanding and the generation of animal models of these diseases for pre-clinical drug development and characterization. Such endeavors have been extensive for Alzheimer, Parkinson, Huntington, Pelizaeus-Merzbacher and prion diseases, amyotrophic lateral sclerosis, and multiple sclerosis (reviewed in Forman et al. 2003; Gow and Sharma 2003; Soto 2003) .
Increasingly, the investigation of neurodegenerative diseases is shifting from the clinical setting, wherein most studies focus on case reports, patient outcomes, and the description and cataloging of pathology, to the basic and translational science realms which seek molecular understanding and the generation of animal models of these diseases for pre-clinical drug development and characterization. Such endeavors have been extensive for Alzheimer, Parkinson, Huntington, Pelizaeus-Merzbacher and prion diseases, amyotrophic lateral sclerosis, and multiple sclerosis (reviewed in Forman et al. 2003; Gow and Sharma 2003; Soto 2003) .
Emerging features of the pathophysiology of these diseases suggest convergent processes including protein aggregation, toxicity, and oxidative stress (reviewed in Johnson and Johnson 2015) . In this regard, the beneficial effect of treating relapsing-remitting multiple sclerosis with oral dimethyl fumarate (Tecfidera formulation) is of interest because of the proposed pharmacological activities of this compound in suppressing the immune system and inhibiting NF-kB signaling. An additional proposed mechanism of action involves liberation and stabilization of the master transcriptional regulator of antioxidative stress pathways, Nrf2, from its E3 ligase-binding partner, Keap-1 (reviewed in Fox et al. 2014) .
Most pre-clinical in vitro and in vivo studies exploring dimethyl fumarate (BG-12 formulation) mechanism of action have focused on immune-mediated effects because of the historical efficacy of fumarate esters in treating psoriasis, MS, and the proposed treatment of other diseases (reviewed in Meissner et al. 2012) . With respect to pre-clinical models of MS, BG-12 appears to reduce early disease phase macrophage activation and infiltration of activated T cells into the spinal cord of mice with myelin-oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE). However, BG-12 appears to be minimally efficacious for immune suppression in the chronic phase of disease (Schilling et al. 2006; Linker et al. 2011) . These data and other studies suggesting BG-12 may have neuroprotective functions rather than, or in addition to, immune suppression properties indicate that further work is needed to elucidate the biological activity of fumaric acid esters.
In this study, we approach this issue by considering nonimmune-mediated white matter disease and have treated a mouse model of oligodendrocyte metabolic stress with daily low-or high-dose BG-12 for 6 weeks. This model, known as the rumpshaker (rsh) mouse, harbors a missense mutation in the Proteolipid protein 1 (Plp1) gene. The encoded mutant protein accumulates in the endoplasmic reticulum, activates the unfolded protein response (UPR), and can trigger apoptosis in mature myelinating oligodendrocytes (Gow et al. 1998; Southwood et al. 2002 Southwood et al. , 2016 . Spasticity and ataxia are manifest around 2 weeks of age in rsh mice, which persists for approximately 1 year. The mice also exhibit cortical spiking and myoclonus (reviewed in Kojovic et al. 2011 ) beginning around 1 month of age that is increasingly frequent for at least 2 months.
Importantly, astrocytes and microglia are activated in white matter tracts of rsh mice, but there is negligible evidence of adaptive immune responses (Southwood et al. 2013) . Thus, this mouse model is useful for assessing the effects of BG-12 activity on the toxicity of protein misfolding, activation of the UPR, neuroprotection, as well as astroglial and innate immune activation in the absence of Band T-cell responses. We find that BG-12 reduces myoclonus frequency but has at best only subtle effects on multiple cell types and signaling pathways. Thus, we find little evidence for suppressing astrocyte and microglial activation, increasing myelination, altering UPR or Nrf2 signaling, and modulating central and peripheral cytokine levels.
Methods
For detailed methods, see the Supporting Information.
Mouse colony
All procedures were approved by IACUC at Wayne State University. Mice showing signs of distress, rough coat, > 20% weight loss, infections, were euthanized. We had maintained rsh mice on a hybrid background > 20 years by outcrossing female rsh carriers to B6C3H/Tac F1 males (Wolf et al. 1983) . Mice were housed in a 12 h light (6 am-6 pm)/dark cycle at 70-75°F and 60% humidity with standard rodent chow (5LOD, Picolab, Brentwood, MO, USA) and tap water ad libitum. The bedding was 1/8 seeding hardwood chips with compressed cotton-fiber nestlet enrichment (NES3600, Ancare, Bellmore, NY, USA).
Surgery for intracranial electrodes
Four 6-week-old male mice (3 9 rsh and 1 9 control) were anesthetized with 2,2,2-tribromoethanol (375 mg/kg) in sterile phosphate-buffered saline. Sterile surgery was performed on a rodent stereotaxic frame (Stoelting, Wood Dale, IL, USA) and isothermal heating pad (Braintree Scientific, Braintree, MA, USA). Six microdrill (Stoelting) burr holes in the skull were positioned (AE 0.5 mm to avoid blood vessels) 2-4 mm lateral to the midline, at Bregma À1.5 mm (electrodes 1 and 6), +1 mm (electrodes 2 and 5) and +2.5 mm (electrodes 3 and 4). Stainless steel screws (Plastics One, Roanoke, VA, USA) were secured with dental cement (Instech, Plymouth Meeting, PA, USA). Mice in their home cage were connected to a tether (Plastics One) for intracranial electroencephalogram recording (iEEG, gain = 8; 0.5 or 1 kHz sampling) using an ADS1299EEG-FE preamplifier and software (Texas Instruments, Dallas, TX, USA). Camcorders (Bell+Howell Products, Durham, NC, USA) captured top and side views of iEEG sessions. Myoclonus was induced by brief stimuli on the hind limb or proximal tail with a flexible polypropylene rod (Videos S2 and S3). The iEEG data were processed in MatLab (R2015b: 8.6.0.267246, Mathworks, Natick, MA, USA) and EEGLAB (ver 13_6_5b, Delorme and Makeig 2004) . Data were filtered and resampled at 250 Hz and referenced to remove electromyogram signals and residual line noise.
Study design and outcomes
The primary outcome measure was myoclonus activity recorded daily during handling. Mice were handled for similar lengths of time so myoclonus activity was proportional to disease activity and the handler was blinded to treatment group. Secondary outcome measures included weekly weighing, rotarod testing, and end-ofstudy quantification of microglial activation, oligodendrocyte metabolic stress, myelin g-ratios, gene expression profiles, and central and peripheral cytokine profiling.
Rotarod and gavage
Mice were trained and tested three times using a 2-day protocol (Day 1 training, Day 2 testing) at P27 to obtain baseline data (Gow et al. 1999) . Following a 2 h rest, mice received tracheal gavage of BG-12 suspended in hydroxymethyl cellulose at 0, 50 or 100 mg/ kg. Dosing was daily for 43 days (Fig. S1 ). Rotarod was repeated weekly. Mice were killed within 24 h of the final gavage.
Immunofluorescence microscopy Mice were perfused intracardially for 15 min with 4% paraformaldehyde in 0.1 M phosphate buffer, pH7.2. Brains and spinal cords were infiltrated with 25% sucrose in 0.1 M phosphate buffer overnight at 4°C and embedded for cryostat sectioning. Ten micrometer sections of transverse spinal cord or sagittal brains were thaw-mounted on Superfrost slides without drying.
Slides were thawed in Tris-buffered saline (TBS), pH7.4, and permeabilized in 0.1% Triton X-100 in TBS for 30 min, or 100% methanol at À20°C for 10 min, blocked in a solution of 2% goat serum, 0.1% gelatin, 0.2% bovine serum albumin, TBS (TBSGBA) for 30 min and primary antibodies applied overnight. Secondary antibodies in TBSGBA were applied for 3 h. Primary antibodies: anti-CC1 (Calbiochem, San Diego, CA, USA); anti-CHOP ; anti-activated caspase 3 (Neuromics, Edina, MN, USA); anti-Iba1 (WAKO, Richmond, VA, USA); anti-CD68 (Abd Serotec, Raleigh, NC, USA); anti-GFAP (Neuromics).
Western blotting
Mice were decapitated and cervical spinal cord rapidly frozen in liquid nitrogen. Tissue was homogenized (Ultra Turrax T 10 homogenizer, Thermo Fisher Scientific, Waltham, MA, USA) for 1 min in 400 lL of 1X Epitomics cell lysis buffer containing 1% Triton X-100, 1 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, protease inhibitors and phosphatase inhibitors PC1 and PC3 (as recommended, Sigma-Aldrich, St Louis, MO, USA), and benzonase (EMD-Millipore, Billerica, MA, USA) in 10 mM TBS. Protein concentrations were determined using BCA assays (Thermo Fisher Scientific) and 1-2 lg of protein/lane (myelin proteins), 6-12 lg (GFAP and Nqo1) or 60-120 lg (Nrf2) were electrophoresed on sodium dodecyl sulfate-polyacrylamide gels (Laemmli 1970) . Proteins were transferred to nitrocellulose Protran membranes (Thermo Fisher Scientific) and developed (Southwood et al. 2012) . Antibodies: anti-GFAP (Neuromics), Nqo1 (Abcam, Cambridge, MA, USA), Nrf2 (Cell Signaling Technology Inc., Danvers, MA, USA), proteolipid protein 1 (PLP1) (AA3) (Gow et al. 1998) , myelin basic protein (MBP) (Covance, Princeton, NJ, USA), a-tubulin (Santa Cruz Biotechnology Inc., Dallas, TX, USA), and b-actin (Sigma-Aldrich).
Electron microscopy
Mice were perfused intracardially for 60 min with 4% paraformaldehyde, 0.5% glutaraldehyde, 4 mM CaCl 2 in 0.15 M sodium cacodylate buffer, pH7.2, and embedded in Araldite 502 (Electron Microscopy Sciences, Hatfield, PA, USA) for transmission electron microscopy according to our established procedures (Devaux and Gow 2008; Southwood et al. 2016) . Gold-silver sections on formvar-coated copper grids (Electron Microscopy Sciences) were stained with ethanolic depleted uranyl acetate and lead citrate. Ten random survey images for analysis (15 000x) were captured (Advanced Microscopy Techniques digital camera) using a Joel 2010 microscope at 100 kV.
Cytokine analysis in brainstem and serum Whole blood (0.3-0.5 mL) from five mice/treatment arm was clotted overnight. Brainstem was harvested from five mice/treatment arm perfused with 5 mL of phosphate-buffered saline and homogenized (Ultra Turrax T 10) for 1 min in 0.4 mL of 0.1 M Tris, pH7.4, 0.15 M NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% sodium deoxycholate, 0.25% Triton X-100, 10 mM phenylmethylsulfonyl fluoride (SigmaAldrich), phosphatase inhibitor cocktails PC1/3 (Sigma-Aldrich), and protease inhibitor cocktail (Sigma-Aldrich). After microcentrifugation at 4°C for 20 min, supernatants were stored at À80°C. Protein concentrations were 6.2 AE 0.6 mg/mL (BCA, Pierce, Life Technologies) and samples were assayed using Luminex multiplex beads (Luminex, Life Technologies, Grand Island, NY, USA). Cytokines: IL-1a, IL-1b, IL-4, IL-6, IL-10, IL-12p70, IL-17, IL-23p19, CXCL1, CXCL10, CCL2, CCL4, CCL5, G-CSF, M-CSF, GM-CSF, TNFa, IFNc.
Quantitative TaqMan PCR from optic nerve Optic nerves were rapidly dissected and frozen in liquid nitrogen. Samples were homogenized for 1 min at 25°C in 0.7 mL of QIAzol (QIAGEN, Germantown, MD, USA). The RNA was then purified using a Qiagen miRNA kit (QIAGEN) for lipid-rich tissues. Samples were tested for linear amplification and linear dilution with TATA-binding protein. The RT reactions were assayed in triplicate in 384-well Taqman assays (BioRad, Hercules, CA, USA). Probes listed in Table S1 .
Statistics
All analyses were performed using Prism (version 6.0 g, GraphPad Software Inc., La Jolla, CA, USA). We examined the myoclonus data using several approaches for robustness of findings: (i) one-way ANOVA with Sidak's post hoc testing, (ii) repeated measures ANOVA with matching by age and left-to-right linear trend for BG-12 dose, (iii) quartile analysis with contingency tables and Chi-square testing. The g-ratios were analyzed by two-way ANOVA for treatment arm with Bonferroni post hoc testing. All other data were analyzed by one-way ANOVA with Sidak's post hoc testing.
Results
In this study, we have focused on myoclonus in male rsh mice as the primary outcome measure for BG-12 treatment in light of a hypothesized role of this compound in neuroprotection (Linker et al. 2011) . Although mutations in the Plp1 gene cause misfolding of the encoded PLP1 and induction of the UPR in oligodendrocytes, the normal functions of glial cells and neurons are heavily interdependent. Thus, it is reasonable to postulate that metabolic stress in rsh oligodendrocytes during development, which causes hypomyelination and oligodendrocyte death, secondarily disrupts neuron function leading to myoclonus or other phenotypes.
Cortical spiking and myoclonus in rsh mice
The rsh mouse epithet (Griffiths et al. 1990 ) derives from stereotypic intention tremors and persistent hind limb ataxia/ spasticity during ambulation (e.g. left hind limb, Video S1). Anecdotally, we have observed apparent myoclonus in rsh males for more than 20 generations, beginning at 4-6 weeks of age and persisting at least 2 months. Event duration approximates 7 s (Fig. 1a) , exemplified by an upward tail flick, generalized flattening/flexion of the trunk, hind limbs, and tail and subsequent forelimb and facial muscle jerks. The mice are sensitive to startle, auditory, and somatosensory stimuli and recovery to normal behavior is rapid. The mice habituate to repetitive stimuli, which protect against additional myoclonic events for several minutes.
To characterize rsh myoclonus, we recorded iEEGs (Fig. 1b) associated with brief tactile stimuli in awake freely behaving mice. The iEEG trace in Fig. 1ci (Video S2) shows resting activity (referenced to channel 4) giving way to 8-10 Hz cortical spiking (Fig. 1cii ) proximal to tactile tail stimulus. Broad muscle responses in the trace (vertical lines) connote myoclonus onset and termination, during which iEEG amplitude and form is similar to both initial resting activity and post-myoclonus recovery. Some events include 8-10 Hz spiking (Fig. 1d , Video S3) but are phenotypically indistinguishable from non-spiking myoclonus. Together, our analysis of rsh iEEG activity reveals myoclonus, most likely of subcortical origin (Caviness 2009; Kojovic et al. 2011) , with consistent physical appearance but variable electrophysiology (compare Videos S2 and S3).
Myoclonus frequency is reduced by BG-12 treatment in rsh mice
The variable myoclonus signatures in rsh mice portend significant difficulties for quantitative analysis, particularly for evaluating BG-12 efficacy. Thus, we quantified myoclonus events as the most consistent primary outcome measure. Average myoclonus activity in rsh males/treatment arm/day (meanAESEM) during a 6 -week BG-12 treatment protocol ( Fig. S1 ) is shown in Fig. 2ai . There is no myoclonus in wild-type mice (not shown for clarity) but occurs in rsh mice with increasing frequency beginning around P30-35 and persisting throughout the study. Twenty-one mice/treatment arm were treated, divided between seven rolling-enrollment experiments.
An overview of cumulative myoclonus activity in rsh mice shows an inverse relationship with BG-12 dose, and Gaussian curve fits estimate a 38% reduction in myoclonus at the high dose after 6 weeks ( Fig. 2ai) . Total myoclonus activity is also plotted as a function of BG-12 dose ( Fig. 2aii ) and shows heterogeneous activity for vehicle and low-dose treatment groups. A contributing factor to this heterogeneity may be the hybrid C57Bl/6Tac 9 C3H/Tac F1 genetic background of our colony to ensure genetic modifiers are not fixed within the population. Genetic modifiers have been demonstrated for several Plp1 mutants (Billings-Gagliardi et al. 1980; Wolf et al. 1983; Al-Saktawi et al. 2003) .
Myoclonus activity in high-dose BG-12 rsh mice mostly clusters in the lower quartiles suggesting treatment-associated suppression. Activity in four mice forms a second cluster in the upper quartile, and a robust regression and outlier removal (ROUT) analysis (Q = 1%) identifies them as outliers. A plausible interpretation is that these mice are non-responders. If so, we also expect non-responders in the other treatment arms, although they cannot be identified by ROUT analysis. Thus, it would be inappropriate to exclude outliers in the high-dose arm.
One solution for non-responders is quartile analysis of the data and Fig. 2aiii summarizes contingency data, in which total myoclonus events from all treatment arms are pooled for quartile stratification. If BG-12 does not affect myoclonus, we expect similar distributions of mice from all treatment arms in each quartile. A Chi-squared analysis (X 2 = 6.27, df = 1) of the first and third quartiles (assuming that non-responders contribute to the fourth quartile) reveals that the treatment arm distributions are asymmetric, and confirms the distribution of high-dose mice in Fig. 2aii . This result suggests that BG-12 reduces myoclonus activity (p = 0.0123).
Combining weekly myoclonus activity provides a clearer picture of BG-12 efficacy during treatment (Fig. 2aiv ). These data replicate the reduction in cumulative activity by BG-12 ( Fig. 2ai) , and two-way repeated measures ANOVA reveals statistical reductions for treatment weeks 5 and 6 (p > 0.03) by approximately 42% in the high-dose BG-12 arm. Treatment arms are statistically indistinguishable through 4 weeks. Thus, we conclude that BG-12 progressively reduces myoclonus after several weeks, compared to vehicle controls.
Motor coordination is not improved by BG-12
In addition to daily measurement of myoclonus activity, mice underwent weekly rotarod training-testing. Test day times-tofall (meanAESEM) for 21 wild type mice/treatment arm ( Fig. 2bi ) are approximately 200 s and we observe no effect of BG-12 dose on performance. The rsh mice perform this test relatively poorly, with times around 100 s (Fig. 2bii) as we previously reported ). However, there are no differences between treatment arms. Weekly weights for all treatment arms (Fig. 2c) show no differences in the trajectory of weight gain, although rsh mice are 10% lighter than controls after 6 weeks of BG-12. Thus, motor coordination is not improved by BG-12 and adverse effects are minimal.
Microglial and astrocyte activation are minimally altered by BG-12 in rsh mice Glial cells undergo significant morphological changes and are robustly activated by the UPR in rsh oligodendrocytes (Southwood et al. 2013) . In contrast, gray matter microglia remain remarkably quiescent and unperturbed by myelin pathology; thus, we focused on dorsal, lateral, and ventral white matter tracts of cervical spinal cord for analysis. Total microglia number in wild-type mice approximates 125 cells/ mm 2 , which is invariant with BG-12 dose (Fig. 3ai ). Microglial density decreases somewhat (100 microglia/ mm 2 ) in rsh white matter, which may be associated with changes in cytokine expression (Fig. S2 ), but BG-12 has minimal impact.
As expected, few CD68 + activated microglia are seen in any wild-type treatment arm (Fig. 3aii) , while these cells are strongly activated at approximately 60 cells/mm 2 in rsh mice treated with placebo, (approximately 60%). In both rsh BG-12-treatment arms, activated microglial density approximates 40 cells/mm 2 , which reflects a statistically significant 20-25% reduction (p = 0.0002). However, the proportion of activated microglia for each treatment arm remains at 50-60%, which is at best a modest reduction in microglial activation. Thus, there appears to be little evidence that the BG-12 mechanism-ofaction includes a major impact on innate immune activation at the levels of microglial morphology or CD68 expression in the context of rsh pathology.
Astrocytes also monitor brain activity and react to pathogenic stimuli such as demyelination or cell death. Markers for astrocytes are less inclusive than microglial markers but anti-GFAP antibodies label 50% or more of the population. Ventral cervical spinal cord sections labeled with antibodies against GFAP and CC-1 (to label oligodendrocytes) show both glial cell types are unperturbed by highdose BG-12 treatment in wild-type mice ( Fig. 3bi and ii) . In rsh mice, there are no major changes in oligodendrocyte abundance associated with BG-12 treatment and cell densities are similar to controls. Astrocytes are strongly activated in white matter tracts from the rsh mice and high-dose BG-12 treatment has no major effect on this activation ( Fig. 3biii and iv).
Cytokine expression levels are minimally impacted by BG-12 treatment In light of the efficacy of fumaric acid esters in moderating autoimmune disease (Atwan et al. 2015; Xu et al. 2015) and the potential for treating additional diseases (Gill and Kolson 2013; Seidel and Roth 2013; Muller et al. 2015) , we anticipated that BG-12 should include suppression of proinflammatory cytokines and/or induction of antiinflammatory cytokines. Accordingly, we measured 18 cytokines in brains from wild-type and rsh mice in all treatment arms. Levels of cytokines in this study are comparable to published reports (Lacerda-Queiroz et al. 2010; de Miranda et al. 2011) .
One-way ANOVA of brainstem homogenates indicate that BG-12 has minimal effects on cytokines (Table 1) , suggesting a lack of broad spectrum modulation of baseline immunity in wild-type mice, or in the rsh activated state. An exception is M-CSF, with modest (21%) reduction in highdose wild-type mice (Fig. S2 ). This reduction is not observed in rsh mice, although cytokine levels are already twofold lower than in controls. In addition, we observe 1.5 to twofold higher levels of IL-4 in rsh over controls. M-CSF promotes macrophage differentiation, survival, and polarization to the M2 phenotype for wound repair (Zhang et al. 2012) ; thus, its suppression by BG-12 may increase microglial susceptibility to cell death as we observe in BG-12-treated rsh mice (Fig. 3) . Further, increased IL-4 in rsh may be promoting microglial polarization toward an M2 phenotype to reduce the likelihood of proinflammatory responses. Finally, the large reduction in IL-12 from rsh mice may help to minimize the risk of M1 macrophage generation and autoimmunity.
Levels of several cytokines in brain are modulated by disease state but not BG-12 In contrast to the general lack of effect of BG-12 in wild-type and rsh mice, expression levels of three cytokines in CNS are regulated by the rsh phenotype. We observe a fourfold reduction in the proinflammatory cytokine IL-12p70 ( Fig. S2a ; p < 0.0001), a twofold reduction in M-CSF levels ( Fig. S2b ; p < 0.0001) in rsh cohorts across all BG-12 treatment groups. We also observe a 1.5-fold increase in the anti-inflammatory cytokine IL-4 in rsh ( Fig. S2c ; p < 0.014). The signaling pathways underlying changes of these cytokines are uncertain, but they may be modulated by secondary effects associated with balancing the activation, survival, and polarization of microglia in rsh mice (Fig. 3) .
Expression of the Nrf2 target gene Nqo1 is modestly induced by BG-12 treatment
In early studies, we demonstrated that the phenotype of rsh mice stems from primary metabolic stress caused by accumulation of mutant Plp1 in the endoplasmic reticulum of oligodendrocytes (Gow et al. 1998; Southwood and Gow 2001; Southwood et al. 2002; ). This pathology activates the UPR and causes cell death. Accordingly, we examined expression of genes associated with the UPR, apoptosis, proliferation, and other disease-response signaling pathways including oxidative stress, innate immunity, and myelinogenesis to identify BG-12 targets that might contribute to our observed reduction of myoclonus in rsh mice (Fig. 2) .
Gene expression levels for all treatment arms in Tables 2  and 3 are normalized to the cognate gene for vehicle-treated wild-type mice (Column 1). Statistically significant fold changes between the three treatment arms for each genotype, as determined from Sidak's post hoc testing, are bolded (i.e., Columns 1 vs. 2 or 3, and Columns 4 vs. 5 or 6). Overall, we observe few gene expression patterns that are modulated by BG-12, which suggests at best that this drug has limited effects on general glial biology.
BG-12 previously has been shown to induce the Nrf2 oxidative stress response pathway by liberating Nrf2 from its complex with the Keap1 E3 ligase and allowing it to regulate transcription of target genes (Linker et al. 2011) . Protein misfolding and UPR induction are often linked to oxidative stress (Malhotra and Kaufman 2007) ; thus, we examined steady-state transcription of the Nfe2 l2 gene encoding this transcription factor. We do not observe low-or high-dose BG-12 dependent changes in Nfe2 l2 gene expression for either wild-type or rsh mice, which is consistent with previous findings that BG-12 acts post-translationally on the Nrf2-Keap1 complex. However, we also observe few, if any, changes in expression of Nrf2 at the protein level or its transcriptional targets (Table 2 , Fig. 4a and c) . While Nqo1 gene expression is modestly induced at the mRNA level by high-dose BG-12 in both wild-type and rsh mice (p < 0.009), we observe no BG-12-associated changes in five other Nrf2 target genes which is surprising because BG-12 mechanism of action has been shown to activate antioxidative stress pathways in vitro. These observations notwithstanding, Hmox1 is induced approximately twofold in rsh mice (p < 0.003) compared to controls; however, we find no changes in glutathione synthesis or the metabolizing enzyme genes, Gss (p > 0.09), Gstm5 (p < 0.001), Gstp1 (p < 0.0001), and Gpx1 (p > 0.99). Further, Hmox1 expression is not influenced by BG-12 treatment in wild-type or rsh mice. On balance, these data suggest that BG-12 has minimal effects on activating Nrf2-associated antioxidant pathways in wild-type and rsh mice.
No changes in major spinal cord astrocyte or myelin proteins by BG-12 treatment
In the absence of changes to steady-state mRNA levels for Gfap or the major myelin genes in BG-12-treated mice compared to their genotype controls (Table 3) , we examined the levels of the encoded proteins in spinal cord to determine if their turnover might be altered by drug treatment. The amount of GFAP is increased by 50%, and the major myelin proteins are reduced by approximately 50%/gram of protein as expected (Fanarraga et al. , 1993 ; however, we observe no dosedependent changes in the levels of GFAP, PLP, DM-20, or MBP in wild-type mice (Fig. 4b and c) , which is consistent with our quantitative polymerase chain reaction data.
Overall, levels of myelin proteins in the rsh mice are lower compared to controls (X/Y samples, 1 lg/lane; rsh/Y, 2 lg/ lane); however, BG-12 has no major effect on the levels of these proteins in rsh/Y mice between treatment arms which is consistent with the quantitative polymerase chain reaction data and the qualitative immunocytochemistry data (Fig. 3b) . We do observe genotype-specific differences in the ratios of PLP:DM-20 between wild-type and rsh/Y mice which have been reported previously (Mitchell et al. 1992) . Thus, rather than a ratio of approximately 6 : 1 in mature wild-type myelin, the ratio in rsh myelin is between 1 : 1 and 3 : 1. These data suggest that myelination in rsh mice is ongoing or is incomplete. Moreover, the data demonstrate that BG-12 does not alter this trajectory which lends weight to the lack of a major effect of this drug on oligodendrocyte metabolism.
BG-12 does not alter rsh myelin g-ratios in optic nerve
Measurement of steady-state mRNA levels for major myelin gene expression and myelin protein levels in littermate wildtype and rsh suggest there are no major effects of BG-12 on myelinogenesis in rsh mice. The amount of myelin in rsh white matter tracts has been previously estimated at approximately 50% of control levels (Mitchell et al. 1992) and our data are in relative agreement (Fig. 5 and Table 3 ). Nevertheless, we examined transverse optic nerves of rsh mice and controls using transmission electron microscopy to determine myelin gratios and assess the calibers of the axons being myelinated. The electron micrographs in Fig. 5ai -iv show fields from gold-silver plastic sections of optic nerve stained with uranyl acetate and lead citrate to visualize compact myelin around axons. Overall myelin compaction is comparable in all treatment arms, although rsh axons ( Fig. 5aiii and aiv) are clearly hypomyelinated compared to controls. A statistical analysis of g-ratios from vehicle-treated mice (Fig. 5bi ) reveals higher g-ratios at all axon diameters in the mutants. Regression analysis indicates that the y-intercepts for both genotypes are similar (p > 0.12), but the slopes are significantly different (p = 0.002), which suggests that larger diameter rsh axons are more severely hypomyelinated than small axons. Analysis of the low (not shown) and high-dose BG-12 groups yield similar findings; the slopes differ (p > 0.004) but not the y-intercepts (p = 0.94). An overall summary of myelin thickness for the six treatment arms is shown in Fig. 5biii , where g-ratios are represented as means AE SEM for two (wild type) or three (rsh) mice/ treatment arm. A two-way ANOVA reveals that there is an overall strong effect of genotype (p = 0.0002) on the g-ratio but a negligible of BG-12 dose (p > 0.65). Expression levels are normalized to TATA-binding protein mRNA for each mouse (n = 6 mice/treatment arm). N.D., not detected; *p < 0.05; **p < 0.01.
Metabolic stress in rsh oligodendrocytes is undiminished by BG-12
Expression of the mutant Plp1 gene in oligodendrocytes of rsh mice during development and in adulthood leads to induction of the UPR, which stems from metabolic stress associated with the accumulation of misfolded PLP1 in the endoplasmic reticulum (Gow et al. 1994 (Gow et al. , 1998 Southwood et al. 2002) . The best marker of UPR activation is the for PLP1/DM-20, MBP (c) Quantification of the western blots in (a) and (b) for each treatment arm. PLP1:DM-20 ratio is~6:1 (4.9 : 1 quantified from duplicate blots) as expected for mature wild-type myelin, while the ratio in rsh myelin is~2 : 1 (1.5 : 1 quantified from duplicate blots). These ratios are consistent with immature active myelination in rsh mice (Mitchell et al. 1992) . Beta-actin and a-tubulin, electrotransfer controls.
transcription factor, CHOP, which accumulates in the nucleus of stressed cells. A morphometric analysis in cervical spinal cord of rsh mice after 6 weeks of treatment with highdose BG-12 shows that the UPR was induced in approximately 25% of oligodendrocytes at the time of perfusion (Fig. 6 ). This proportion of cells is indistinguishable from low-dose BG-12 and vehicle-treated controls, indicating that BG-12 does not suppress the UPR in metabolically stressed cells. Thus, the mechanism of action of BG-12 in reducing myoclonus is unlikely to be associated with decreasing levels of protein misfolding in rsh oligodendrocytes. In addition to CHOP expression, we find that low-or highdose BG-12 does not generally alter expression of 11 UPR genes, either in wild-type or rsh mice with possible exceptions of the master transcriptional regulator of the PERK pathway, Atf4, and the endoplasmic reticulumassociated degradation gene, Derlin2. In these cases, the effects of BG-12 are modest and inconsistent between the wild-type and rsh cohorts; thus, we conclude that the changes are unlikely to be biologically relevant.
Cell death and cell cycle are not modulated by BG-12 treatment During development, apoptosis of oligodendrocytes in cervical spinal cord increases steadily from birth to approximately 3-4 weeks of age and then subsides to undetectable levels by 6-8 weeks . We examined apoptosis levels in P70 rsh mice to determine if treatment with BG-12 for 6 weeks altered levels of cell death. From 1000 to 2000 CC-1 + oligodendrocytes/mouse, we find that oligodendrocyte Myelinated axons are more numerous in controls than rsh mice. The g-ratios from wild-type and rsh mice treated with (bi) 0 or (bii) 100 mg/kg BG-12, plotted against axon diameter. (biii) Summary data showing gratios for all treatment arms (mean AE SEM). Two-way ANOVA indicates that average gratios are significantly greater for rsh than wild-type mice (F (1,9) = 36.4; p < 0.0002). Little impact of BG-12 on myelin thickness in wild-type or rsh mice (F (2,9) = 0.45; p > 0.6). Scale bar in (d) 500 nm.
apoptosis is undetectable in mice from all six treatment arms (n = 3/arm, data not shown). These data indicate that BG-12 action does not exacerbate metabolic stress and induce cell death. However, we are unable to determine from our analysis if this drug might reduce apoptosis levels by, for example, reducing UPR-associated stress in oligodendrocytes. We also find no evidence of BG-12-dependent expression changes for the apoptosis-regulatory genes Bcl2, Bax, Bak, or Bim (p ≥ 0.05) or critical regulators of the cell cycle, p21
Cip and Trp53 (p > 0.19). Nevertheless, we do observe genotype-associated expression changes for many of these genes, which are consistent with our previous studies and those of other groups (Mitchell et al. 1992; Southwood et al. 2002 Southwood et al. , 2013 Barrie et al. 2010; Radecki and Gow 2013) . Thus, together, these data convincingly demonstrate that BG-12 neither augments nor represses UPR signaling at the levels of arrested protein synthesis, molecular chaperone expression, endoplasmic reticulum-associated degradation, apoptosis, or cell proliferation.
Discussion
Success in the clinical application of Tecfidera to treat MS has sparked intense interest in the mechanism of action of fumaric acid esters. Pre-clinical animal and in vitro model studies suggest cellular targets for these compounds associated with immunomodulation and neuroprotection; however, consensus about the metabolic and signaling pathways by which fumarates ameliorate disease is limited. Herein, we tested the efficacy of daily low and high doses of the dimethyl fumarate formulation, BG-12, to reduce myoclonus in the rsh mouse model of oligodendrocyte metabolic stress. Our approach takes advantage of several features of the rsh phenotype including the known etiology of protein misfolding in oligodendrocytes, secondary and non-neurodegenerative involvement of neurons in the pathophysiology, secondary activation of innate immune responses, and the absence of significant adaptive immune activation.
Myoclonus in humans is a non-specific clinical sign of multiple subtypes that are comorbid with diffuse pathologies such as neurodegeneration, inflammatory diseases like multiple sclerosis and leukodystrophies (Caviness 2009; Kojovic et al. 2011) . Subcortical myoclonus, which is consistent with our data from rsh mice (Fig. 1) , affects facial and fore limb regions bilaterally and can be induced by startle, tactile, and auditory stimuli. The rsh iEEGs also reveal cortical spiking in proximity to myoclonus, but it is unclear whether these abnormalities are coupled or separable. In any case, our study focuses on BG-12 efficacy to moderate myoclonus.
Several mutant strains with Plp1 gene coding region mutations have been characterized (Hudson 2003) , most having severe disease beginning at P13. These mutants exhibit myoclonus/seizures from P21, with rapidly increasing intensity correlated with depletion of the oligodendrocyte precursor pool, and rarely live beyond P30 (Skoff 1982; Ghandour and Skoff 1988; Billings-Gagliardi et al. 2001) . In contrast, the intensity, if not the frequency, of myoclonus in rsh mice is stable over time. Nevertheless, this phenotype can be exacerbated by genetic modifiers like gene deletions or backcrossing to inbred strains, leading to degenerative disease (Southwood et al. 2002 (Southwood et al. , 2016 Al-Saktawi et al. 2003) . Thus, myoclonus/ seizure frequency is correlated with disease severity.
Our six-arm, blinded, rolling-enrollment design (Fig. S1 ) facilitates several statistical analyses. We find both low-and high-dose BG-12 significantly reduce startle and tactileinduced myoclonus by approximately 30% compared with vehicle-treated controls and wild-type mice in all treatment arms (Fig. 2) . We identified outlier rsh mice that appear nonresponsive to high-dose BG-12 and exhibit comparable myoclonus activity to mice in the vehicle and low-dose BG-12 groups (Fig. 2aii) . Because of the mixed background strain used to maintain our breeding colonies, the presence of non-responders has implications for genetic pathways associated with disease amelioration by BG-12. However, this study is underpowered for assessing this issue.
In spite of reduced myoclonus in rsh mice, we observe no significant improvement in myelination of rsh optic nerve axons by BG-12, suggesting that this compound only subtly benefits oligodendrocyte metabolism to promote myelination. For example, we observe no differences in UPR activation in rsh cohorts, as determined by CHOP expression (Fig. 6 ) or other UPR-associated genes (Table 3) . From previous work, we do not expect changes in rsh oligodendrocyte survival because apoptosis is minimal in P70 mice , and neither caspase 3 + nor TUNEL + oligodendrocyte are detectable in any treatment arm. In addition, proapoptotic Approximately, 25% of oligodendrocytes in vehicle-treated rsh mice are undergoing metabolic stress and activation of the UPR, which is not altered by gene expression is at best minimally and/or inconsistently altered in rsh mice compared to controls (Table 3) . Thus, fumarate may have direct benefits for other cell types although the mechanism is currently unclear.
In addition to imperceptible effects of BG-12 on oligodendrocytes, we find little impact on motor coordination (Fig. 2) , perhaps because performance is predominantly white matter-dependent, rather than cortical, and myoclonus stimuli rarely occur during rotarod. Thus, test performance is separable from sensitivity to the stimuli that drive myoclonus. The correlation between myoclonus/seizure activity and disease severity in Plp1-mutant mice suggests that the rsh phenotype is ameliorated by BG-12, perhaps through effects on neurons that render them less susceptible to synchronous activity. In this regard, previous studies have proposed that BG-12 is neuroprotective and reduces glutamate excitotoxicity (Luchtman et al. 2016) , which is unknown in rsh mice but is of future interest.
In view of the efficacy of fumaric acid esters in treating psoriasis and MS (Meissner et al. 2012) , it is reasonable to postulate that BG-12 might involve suppression of immune cell activity or some combination of proinflammatory or antiinflammatory cytokine modulation in rsh mice (Schilling et al. 2006) . However, we do not observe broad innate immune suppression by either low-or high-dose BG-12, although the primary oligodendrocyte pathology causes dramatic induction of microglia in vehicle-treated rsh mice (Fig. 3) . Previous studies in EAE show mixed results for the effect of fumarates on activated microglia, from 90% in the acute phase to 0% in chronic disease (Schilling et al. 2006; Linker et al. 2011) ; so, it is difficult to determine whether the change we observe is biologically relevant. We also previously demonstrated minimal adaptive immune contributions to pathophysiology in these mutants (Southwood et al. 2013) . Further, we find few BG-12-associated changes in either CNS or peripheral cytokines from treated mice compared to vehicle controls (Table 1, Table S2 ) despite changes in several of these molecules associated with the rsh phenotype, including IL-1a, IL-12p70 in serum and brain parenchyma, respectively. Thus, together, these data suggest that BG-12 is unlikely to act through suppression of immune responses in rsh mice, although we cannot exclude the possibility that this compound ameliorates the phenotype through changes in minor cell populations not detected using tissue-and serum-based immunoassays; such changes have been demonstrated in focal demyelinating models (SchulzeTopphoff et al. 2016) .
Pre-clinical studies involving experimentally induced autoimmune disease in mice have also suggested that BG-12 may ameliorate acute phase symptoms by activating antioxidant pathways (Linker et al. 2011) . Indeed, fumaric acid esters are thought to participate in succinylation of cytoplasmic proteins, such as the E3 ligase Keap-1, which results in stabilization and nuclear translocation of its binding partner, Nrf2, to induce expression of antioxidant response genes like Nqo1, Hmox1, and Gst (reviewed in Fox et al. 2014) . This mechanism has gained support in recent years because of the apparent involvement of protein aggregation, oxidative stress, and glutathione depletion in MS and animal models (Southwood et al. 2002; Lin et al. 2005; Andrews et al. 2006; Linker et al. 2011; Aoyama and Nakaki 2013; Ferreira et al. 2013) .
Our enthusiasm for such an explanation with BG-12 in rsh mice is tempered for several reasons. First, we do not observe expression changes in Nrf2 or its transcriptional targets, with the possible exception of Nqo1 induction (30%) at the level of steady-state mRNA (not protein) in the mutants. We cannot formally exclude some effect of BG-12 on innate immunity in deference to recent data that BG-12 may moderate immune cells independently of Nrf2 (SchulzeTopphoff et al. 2016) . Second, induction of Hmox1 in rsh mice may reflect activation of macrophages with a preference for the M2 phenotype (Han et al. 2016) ; however, Hmox1 expression is not regulated by BG-12, which indicates this drug has no significant effects on macrophage activation state or function. Third, expression levels of multiple antioxidant pathway genes are unchanged or reduced in this study and an earlier study in rsh mice (Southwood et al. 2013) , suggesting that BG-12 does not exhibit significant antioxidative stress activity in glia or neurons (Table 2) . Fourth, a recent study of EAE in Nrf2-null mice shows that BG-12 is equally protective for these mutants compared to wild-type controls (Schulze-Topphoff et al. 2016) .
The final reason we do not consider antioxidation activity of BG-12 to account for disease amelioration in rsh mice stems from studies with another myelin genetic mutant, the shiverer (shi) mouse. The pathophysiology of this animal arises from partial deletion of the Myelin basic protein (Mbp) gene, which encodes the major myelin protein MBP and involves increased mitochondrial density in axons, cytochrome c oxidase activity, and oxidative stress (Andrews et al. 2006) . Billings-Gagliardi et al. (2001) demonstrated that interbreeding shi and rsh mice does not exacerbate the shi phenotype, which would not be expected if the rsh pathology involves significant oxidative stress.
With the apparent absence of immune suppressant activity, diminished UPR or improved myelination in oligodendrocytes, or activation of antioxidative stress pathways in the face of reduced myoclonus activity, we postulate that the BG-12 dose-dependent reduction of myoclonus in rsh mice may stem from effects in neurons. We have been unable to test such mechanisms in this study, which was not designed to assess the impact of BG-12 treatment on neuronal electrophysiology because of the variable levels of cortical activity within and between mice. However, such studies are of future interest and may shed light on the secondary consequences of white matter diseases for cortical function.
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Significance statement
The last 5 years have seen an upswing in Food and Drug Administration-approved drugs for treating multiple sclerosis. Mechanisms of action are known for some, but for others like dimethyl fumarate there is at best a broad understanding. Preclinical studies have involved testing dimethyl fumarate in autoimmune-mediated rodent models such as experimental autoimmune encephalomyelitis and suggest that this drug acts through immune suppression and/or antioxidative stress pathways regulated by the transcription factor Nrf2. We test this hypothesis directly using a non-immune-mediated model, where pathology arises from metabolic stress and the unfolded protein response in oligodendrocytes of rumpshaker mice. Our results are significant because they demonstrate disease amelioration apparently not involving broad immune suppression or metabolic stress pathways in oligodendrocytes.
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